Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.76 as of 2026-10-06T13:40:49.716Z.
Consensus retrieved: 2026-10-06T08:50:08.990Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T13:40:49.716Z.
Quote observation: 2026-10-06T13:39:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 725adddd40c1a2280488f538213825861a91d0760fd62c66cabbd6cf27e99fae
Forward PE Ratio (18.76) = Dated Quote Price ($19.70) / Consensus Forward EPS ($1.05)
FORWARD PE RATIO
18.76
SECTOR MEDIAN · HEALTHCARE
19.20
median of 146 covered companies
CURRENT VS SECTOR MEDIAN
-2.32%
vs the sector median at left
Anika Therapeutics, Inc.
Market Cap
$263.58M
Forward PE Ratio
18.76
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $263.58M | 18.76 |
| Century Therapeutics, Inc. (IPSC)vs › | $264.37M | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.42M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.40M | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A |
| AC Immune S.A. (ACIU)vs › | $271.74M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $278.05M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $278.74M | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $246.30M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
18.8
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $19.70, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.05 | $1.04 – $1.06 | 1 | 18.8x |
| 2027-12-31 | $0.95 | $0.94 – $0.96 | 1 | 20.7x |
| 2028-12-31 | $1.15 | $0.89 – $1.41 | 2 | 17.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
